As of the beginning of this year the Journal 'HeartDrug' is affiliated with the Working Group 'Cardiovascular Pharmacology and Drug Therapy'. The ESC Working Groups were created after the Amsterdam Congress in 1976 for the study of specific topics based on the proposals of the Board and after approval by the General Assembly. There are 27 Working Groups established as official work groups of the European Society of Cardiology. Within the ESC Board, a Councillor-in-charge of the Working Groups is elected for two years (T.F. Lüscher, Zurich, Switzerland). Following the restructuring of the Working Groups of the ESC, the Working Group on Cardiovascular Pharmacology and Drug Therapy is now in the Clinical Science Group in Cluster 1 together with the Working Groups on Rehabilitation and Exercise Physiology, Epidemiology and Prevention, and Cardiovascular Nursing.
The following shall give our readers a short overview and introduction into the activities of this particular group. For more information please go to http:// www.escardio.org/society/WG/wg2.htm.
The Editors

Members
Presently our Working Group has 105 members. According to the suggestions made by the Science Council of the ESC, application for membership in our Working Group should be made in writing to the Chairman of the Working Group accompanied by a written statement of two members of the Working Group reflecting the applicant's qualifications, plus a copy of the applicant's CV including a list of the three most recent relevant papers. 
Membership
All members of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy should be either a member of a National Society or a Fellow of the European Society of Cardiology (FESC) or any other person with a distinguished interest in the field cardiovascular pharmacology.
News from the ESC Working Group
Potential members can apply either directly (see application form on the Working Group web-site) or through a proposal to the Chairman of the Working Group submitting a brief curriculum vitae including relevant references. The Chairman presents the applications from suitable new members to the Nucleus for ratification. Unsuitable applicants (as far as formal requirements are concerned) may be rejected by a majority vote of the Nucleus.
If an application is rejected by the Nucleus, there is no obligation to give reasons to the applicant. The membership shall be granted for life unless the member is expelled from his National Society belonging to the ESC, in which case his/her membership of the Working Group will automatically cease to exist. Currently no membership fee is required.
Aims
E To promote and organize research in the field of cardiovascular pharmacology and drug therapy E To gather and exchange information regarding research and related activities within the Working Group E To organize teaching workshops on topics related to cardiovascular pharmacology and drug therapy E To hold regular meetings of the Working Group on specific topics E To be involved in task forces of the European Society of Cardiology related to cardiovascular pharmacology E To contribute to the organisation and preparation of the Annual Congress of the ESC E To participate and support other scientific meetings and symposia.
Activities
E To assist the Chairman and Vice-chairman in administration and organisation of the Working Group E To propose the Vice-chairman, the Secretary and the Treasurer to the General Assembly of the members for election E To provide proposals for the scientific sessions of the Working Group during the Annual Congress of the ESC E The Nucleus of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy will meet at the Annual Congress of the ESC and at least at one other occasion each year.
Working Group Activities during the ESC Congress 2003
Both the next nucleus meeting and the next business meeting (with all members of the WG) will take place at the ESC Congress 2003 in Vienna.
The Nucleus meeting of the Working Group will be held on Sunday, 31 August, from 10:00 to 11:00 in the 'ESC WG 1' meeting room at the Congress Centre in Vienna.
The Business meeting of the Working Group will be held on Monday, September 1st, from 12:45 to 13:45 in the 'Madrid' meeting room (Blue Zone) at the Congress Centre in Vienna. 
Registries, Survey
Together with the Working Group on Epidemiology, we presently are performing a survey on angina treatment patterns in Europe (characteristics of a contemporary population with angina pectoris in Europe, W. Klein, J.R. Hampton).
Study Groups
Heart Failure in Clinical Practice (Ettore Ambrosioni) Treatment of Cardiovascular Disorders in Patients with Multimorbidity (Ferenc Follath) Stroke Prevention in Patients with Cardiovascular Diseases (Philippe Lechat)
Task Forces
The Working Group on Cardiovascular Pharmacology and Drug Therapy is involved in ongoing task forces on E Bacterial Endocarditis E the Joint Study Group on Treatment of Refractory Angina E the 2nd Joint Task Force on Prevention of Coronary Heart Disease in Clinical Practice E the Update of Task Force on Congestive Heart Failure
